These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

458 related items for PubMed ID: 19222510

  • 1. Randomized, double-blind, placebo-controlled, proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis.
    Goadsby PJ, Ferrari MD, Csanyi A, Olesen J, Mills JG, Tonabersat TON-01-05 Study Group.
    Cephalalgia; 2009 Jul; 29(7):742-50. PubMed ID: 19222510
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of tonabersat, a gap-junction modulator, in the acute treatment of migraine: a double-blind, parallel-group, randomized study.
    Dahlöf CG, Hauge AW, Olesen J.
    Cephalalgia; 2009 Nov; 29 Suppl 2():7-16. PubMed ID: 19723121
    [Abstract] [Full Text] [Related]

  • 3. Tonabersat, a gap-junction modulator: efficacy and safety in two randomized, placebo-controlled, dose-ranging studies of acute migraine.
    Silberstein SD, Schoenen J, Göbel H, Diener HC, Elkind AH, Klapper JA, Howard RA.
    Cephalalgia; 2009 Nov; 29 Suppl 2():17-27. PubMed ID: 19723122
    [Abstract] [Full Text] [Related]

  • 4. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R, Schreiber C.
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [Abstract] [Full Text] [Related]

  • 5. Effects of tonabersat on migraine with aura: a randomised, double-blind, placebo-controlled crossover study.
    Hauge AW, Asghar MS, Schytz HW, Christensen K, Olesen J.
    Lancet Neurol; 2009 Aug; 8(8):718-23. PubMed ID: 19570717
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of carisbamate for the treatment of migraine in a randomized, double-blind trial.
    Cady RK, Mathew N, Diener HC, Hu P, Haas M, Novak GP, Study Group.
    Headache; 2009 Feb; 49(2):216-26. PubMed ID: 19222595
    [Abstract] [Full Text] [Related]

  • 7. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
    Aurora SK, Gawel M, Brandes JL, Pokta S, Vandenburgh AM, BOTOX North American Episodic Migraine Study Group.
    Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098
    [Abstract] [Full Text] [Related]

  • 8. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.
    Dodick DW, Mauskop A, Elkind AH, DeGryse R, Brin MF, Silberstein SD, BOTOX CDH Study Group.
    Headache; 2005 Apr; 45(4):315-24. PubMed ID: 15836567
    [Abstract] [Full Text] [Related]

  • 9. Montelukast for migraine prophylaxis: a randomized, double-blind, placebo-controlled study.
    Brandes JL, Visser WH, Farmer MV, Schuhl AL, Malbecq W, Vrijens F, Lines CR, Reines SA, Protocol 125 study group.
    Headache; 2004 Jun; 44(6):581-6. PubMed ID: 15186302
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials.
    Shuhendler AJ, Lee S, Siu M, Ondovcik S, Lam K, Alabdullatif A, Zhang X, Machado M, Einarson TR.
    Pharmacotherapy; 2009 Jul; 29(7):784-91. PubMed ID: 19558252
    [Abstract] [Full Text] [Related]

  • 11. Tonabersat for migraine prophylaxis: a systematic review.
    Cao Y, Zheng OJ.
    Pain Physician; 2014 Jul; 17(1):1-8. PubMed ID: 24452641
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention--a randomized, double-blind, multicentre, placebo-controlled study.
    Diener HC, Pfaffenrath V, Schnitker J, Friede M, Henneicke-von Zepelin HH.
    Cephalalgia; 2005 Nov; 25(11):1031-41. PubMed ID: 16232154
    [Abstract] [Full Text] [Related]

  • 13. A double-blind study of SB-220453 (Tonerbasat) in the glyceryltrinitrate (GTN) model of migraine.
    Tvedskov JF, Iversen HK, Olesen J.
    Cephalalgia; 2004 Oct; 24(10):875-82. PubMed ID: 15377319
    [Abstract] [Full Text] [Related]

  • 14. Tonabersat, a novel gap-junction modulator for the prevention of migraine.
    Silberstein SD.
    Cephalalgia; 2009 Nov; 29 Suppl 2():28-35. PubMed ID: 19723123
    [Abstract] [Full Text] [Related]

  • 15. [Gap junctional intercellular communication: a new mechanism in pathophysiology of migraine with aura. Therapeutic applications].
    Sarrouilhe D, Dejean C.
    Pathol Biol (Paris); 2012 Dec; 60(6):392-8. PubMed ID: 22633071
    [Abstract] [Full Text] [Related]

  • 16. A randomized double-blind placebo-controlled trial of thioctic acid in migraine prophylaxis.
    Magis D, Ambrosini A, Sándor P, Jacquy J, Laloux P, Schoenen J.
    Headache; 2007 Jan; 47(1):52-7. PubMed ID: 17355494
    [Abstract] [Full Text] [Related]

  • 17. Acupuncture in migraine prevention: a randomized sham controlled study with 6-months posttreatment follow-up.
    Alecrim-Andrade J, Maciel-Júnior JA, Carnè X, Severino Vasconcelos GM, Correa-Filho HR.
    Clin J Pain; 2008 Feb; 24(2):98-105. PubMed ID: 18209514
    [Abstract] [Full Text] [Related]

  • 18. A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches.
    Relja M, Poole AC, Schoenen J, Pascual J, Lei X, Thompson C, European BoNTA Headache Study Group.
    Cephalalgia; 2007 Jun; 27(6):492-503. PubMed ID: 17428299
    [Abstract] [Full Text] [Related]

  • 19. European multicenter trial of nimodipine in the prophylaxis of classic migraine (migraine with aura). Migraine-Nimodipine European Study Group (MINES).
    Headache; 1989 Nov; 29(10):639-42. PubMed ID: 2693406
    [Abstract] [Full Text] [Related]

  • 20. Early vs. non-early intervention in acute migraine-'Act when Mild (AwM)'. A double-blind, placebo-controlled trial of almotriptan.
    Goadsby PJ, Zanchin G, Geraud G, de Klippel N, Diaz-Insa S, Gobel H, Cunha L, Ivanoff N, Falques M, Fortea J.
    Cephalalgia; 2008 Apr; 28(4):383-91. PubMed ID: 18294251
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.